Abstract
TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antitubercular Agents / chemistry
-
Antitubercular Agents / pharmacology*
-
Antitubercular Agents / therapeutic use*
-
Cytochrome P-450 Enzyme Inhibitors*
-
Cytochrome P-450 Enzyme System / genetics
-
Cytochrome P-450 Enzyme System / metabolism
-
Host-Pathogen Interactions / drug effects
-
Host-Pathogen Interactions / genetics
-
Humans
-
Molecular Targeted Therapy*
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / enzymology*
-
Mycobacterium tuberculosis / genetics
-
Tuberculosis / drug therapy*
-
Tuberculosis / microbiology
Substances
-
Antitubercular Agents
-
Cytochrome P-450 Enzyme Inhibitors
-
Cytochrome P-450 Enzyme System